Home > Insider Trading > Filing (0001213900-23-097043)

Filing Details

Accession Number:: 0001213900-23-097043
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-19 18:00:01
Reporting Period:: 2023-12-15

Accepted Time:: 2023-12-19 18:00:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1445499	Impel Pharmaceuticals Inc	IMPL	Pharmaceutical Preparations (2834)	263058238

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1618788	Vivo Capital Fund Viii, L.p.	192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No
1618789	Vivo Capital Viii, Llc	192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No
1628048	Vivo Capital Surplus Fund Viii, L.p.	192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-12-15	87,934	$0.29	2,447,181	No	4	S	Indirect	By: Vivo Capital Fund VIII, L.P.
Common Stock	Disposition	2023-12-15	12,066	$0.29	337,608	No	4	S	Indirect	By: Vivo Capital Surplus Fund VIII, L.P.
Common Stock	Disposition	2023-12-18	209,029	$0.11	2,238,152	No	4	S	Indirect	By: Vivo Capital Fund VIII, L.P.
Common Stock	Disposition	2023-12-18	28,682	$0.11	308,926	No	4	S	Indirect	By: Vivo Capital Surplus Fund VIII, L.P.
Common Stock	Disposition	2023-12-19	208,657	$0.08	2,029,495	No	4	S	Indirect	By: Vivo Capital Fund VIII, L.P.
Common Stock	Disposition	2023-12-19	28,632	$0.08	280,294	No	4	S	Indirect	By: Vivo Capital Surplus Fund VIII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By: Vivo Capital Fund VIII, L.P.
No	4	S	Indirect	By: Vivo Capital Surplus Fund VIII, L.P.
No	4	S	Indirect	By: Vivo Capital Fund VIII, L.P.
No	4	S	Indirect	By: Vivo Capital Surplus Fund VIII, L.P.
No	4	S	Indirect	By: Vivo Capital Fund VIII, L.P.
No	4	S	Indirect	By: Vivo Capital Surplus Fund VIII, L.P.

Footnotes

The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.44 to $0.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.30 to $0.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.10 to $0.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.